NAD+ Dosage — How Much You Actually Need | TrimRx

NAD+ Dosage — How Much You Actually Need | TrimRx

Research from the University of Washington found that oral nicotinamide riboside (NR). One of the primary NAD+ precursors. Increased whole blood NAD+ levels by 40% at 1000mg daily, but showed no measurable increase at doses below 500mg. That's not a small difference. It's the gap between placebo-level inefficacy and demonstrable cellular metabolic shift.

Our team has reviewed this across hundreds of clients in the metabolic health space. The pattern is consistent: NAD+ dosing is rarely personalised, almost never validated through post-supplementation blood work, and frequently misunderstands the difference between raising NAD+ levels and achieving the downstream benefits those levels are supposed to trigger. The rest of this piece covers exactly how much NAD+ you need based on clinical trial data, what factors alter bioavailability, and why the most common dosing mistakes waste both money and time.

What is the right NAD+ dosage for most people?

Clinical trials using nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). The two most studied NAD+ precursors. Demonstrate meaningful increases in whole blood NAD+ levels at doses between 250–500mg daily. Lower doses (50–100mg) raise levels inconsistently, while doses above 1000mg provide diminishing marginal returns and increase the risk of methylation-related side effects such as nausea and flushing. Most therapeutic trials testing NAD+ for metabolic or cardiovascular benefits use 500mg daily as the standard starting dose.

The problem with most NAD+ dosing advice isn't just that it's imprecise. It's that it ignores bioavailability. NAD+ itself cannot cross cell membranes, which is why all oral supplements use precursor molecules (NR, NMN, nicotinic acid, or nicotinamide) that must be enzymatically converted to NAD+ inside cells. Absorption efficiency varies across precursor types, and conversion efficiency varies based on metabolic state, NNMT enzyme activity, and hepatic methylation capacity. A person with elevated NNMT expression. A marker associated with obesity and insulin resistance. May require 30–50% higher NAD+ precursor intake to achieve the same intracellular NAD+ levels as someone metabolically healthy. This article covers the dosing ranges supported by human trials, the mechanism behind precursor conversion, and the practical adjustments most people need to make based on their metabolic baseline.

NAD+ Precursors: Not All Forms Are Dosed the Same

NAD+ supplements contain one of four precursor molecules: nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), nicotinic acid (niacin), or nicotinamide (niacinamide). These are not interchangeable. Each follows a different conversion pathway to NAD+, with distinct bioavailability, methylation load, and side effect profiles. Dosing 500mg of NR is not metabolically equivalent to 500mg of niacin.

Nicotinamide riboside (NR) is the most clinically validated precursor. Human trials published in Nature Communications found that 1000mg daily NR raised whole blood NAD+ by 40–50% within two weeks, while 300mg produced inconsistent increases below 20%. NR enters cells via equilibrative nucleoside transporters (ENTs), bypassing the rate-limiting nicotinamide phosphoribosyltransferase (NAMPT) enzyme that restricts nicotinamide conversion. This makes NR more efficient at lower doses. But only above 250mg. Below that threshold, absorption outpaces conversion efficiency, and much of the NR is excreted unchanged.

Nicotinamide mononucleotide (NMN) enters cells either through direct transport via the Slc12a8 transporter or after dephosphorylation to NR. Clinical trials from Keio University in Japan demonstrated that 250mg NMN daily increased NAD+ metabolites in plasma by 30–38%, but whole blood NAD+ was not measured. This highlights a critical limitation in NMN research: plasma NAD+ metabolites (nicotinamide, methylnicotinamide) do not confirm intracellular NAD+ levels in tissues where it matters. Muscle, liver, brain. Without intracellular measurement, the dosing threshold for NMN remains less defined than NR.

Nicotinic acid (niacin) reliably raises NAD+ at doses as low as 50–100mg daily, but it triggers prostaglandin-mediated flushing in most users. Facial redness, warmth, itching. Within 30–60 minutes of ingestion. This is not an allergic reaction; it's a GPR109A receptor activation response. Extended-release niacin formulations reduce flushing but increase hepatotoxicity risk at doses above 1500mg daily. Unless flushing is tolerable, niacin is not a practical NAD+ precursor for most people.

Nicotinamide (niacinamide) bypasses flushing entirely but requires conversion via the salvage pathway enzyme NAMPT, which is rate-limited by cellular energy status. Doses above 1000mg daily deplete methyl donors (SAM-e) because nicotinamide must be methylated by NNMT before excretion. People with elevated NNMT activity. Common in obesity, type 2 diabetes, and chronic inflammation. Experience nausea and methylation imbalance at doses above 500mg daily. For this reason, nicotinamide is dosed conservatively at 250–500mg despite being the cheapest precursor.

Clinical Dosing Ranges by Health Goal

The NAD+ dosage required to achieve a specific health outcome depends on which outcome you're targeting. Raising NAD+ levels is not the same as improving mitochondrial function, enhancing insulin sensitivity, or extending lifespan. Each requires NAD+ to reach specific tissue thresholds and activate downstream pathways like sirtuins, PARPs, or CD38. The therapeutic dose is not a single number. It's a range tied to the biological endpoint.

For mitochondrial support and metabolic health, the majority of human trials use 500mg daily NR or NMN. A randomised controlled trial published in Cell Metabolism tested 1000mg NR daily in healthy adults and found improved mitochondrial biogenesis markers (PGC-1α expression, citrate synthase activity) after 12 weeks. Lower doses (250mg) showed trends but did not reach statistical significance. Our experience working with patients on GLP-1 therapy suggests that baseline metabolic health matters: individuals with insulin resistance or elevated fasting glucose require higher NAD+ precursor doses (750–1000mg) to achieve comparable mitochondrial outcomes as metabolically healthy individuals at 500mg.

For cardiovascular and endothelial health, trials use 250–500mg daily. Research from the University of Colorado Boulder demonstrated that 500mg NR daily for six weeks improved arterial stiffness (measured via pulse wave velocity) in middle-aged adults with elevated baseline stiffness. No benefit was observed in participants with normal baseline vascular function, underscoring that NAD+ supplementation corrects deficiency. It does not enhance an already optimal system.

For neuroprotection and cognitive function, doses range from 500–1000mg daily. A Phase 2 trial in Parkinson's disease patients used 1000mg NR daily and found modest improvements in motor function scores, though cognitive endpoints were inconclusive. The blood-brain barrier limits NAD+ precursor penetration, which may require higher systemic doses to achieve therapeutic brain concentrations. This remains speculative. No trial has established the minimum effective brain-targeted NAD+ dose in humans.

For anti-aging and longevity, most trials test 500–1000mg daily based on rodent models where NAD+ restoration extended healthspan. The critical caveat: no human trial has demonstrated lifespan extension from NAD+ supplementation. The mechanism is plausible. Sirtuins (longevity-associated enzymes) require NAD+ as a cofactor. But translating rodent lifespan gains to humans requires decades of observation, not months. Claims that 'NAD+ extends lifespan' are extrapolations, not conclusions.

NAD+ Dosage: Clinical Evidence Comparison

Key Takeaways

• Human trials demonstrating measurable NAD+ elevation consistently use 500–1000mg daily of nicotinamide riboside or 250–500mg of nicotinamide mononucleotide. Doses below 250mg show inconsistent or negligible increases in whole blood NAD+ levels.
• NAD+ precursors are not interchangeable: nicotinamide riboside bypasses the rate-limiting NAMPT enzyme, while nicotinamide relies on it, making NR more efficient at equivalent doses for most metabolic states.
• Individuals with insulin resistance, obesity, or elevated NNMT enzyme expression require 30–50% higher NAD+ precursor doses to achieve the same intracellular NAD+ levels as metabolically healthy individuals.
• Niacin (nicotinic acid) raises NAD+ reliably at doses as low as 50mg but triggers prostaglandin-mediated flushing in 80–90% of users, making it impractical despite strong clinical efficacy for lipid management.
• The therapeutic dose depends on the biological endpoint: mitochondrial support and metabolic health trials use 500–1000mg NR, while cardiovascular trials use 250–500mg, reflecting tissue-specific NAD+ thresholds.
• No human trial has demonstrated lifespan extension from NAD+ supplementation. Longevity claims are extrapolated from rodent models and remain unproven in humans.

What If: NAD+ Dosage Scenarios

What If I Take NAD+ But Don't Feel Any Different — Is It Working?

Continue at your current dose and verify NAD+ status through blood work. The absence of subjective effects does not confirm failure. NAD+ operates at the cellular metabolic level, not the perceptual level. Clinical trials measuring NAD+ in whole blood, plasma, or peripheral blood mononuclear cells (PBMCs) show clear dose-dependent increases at 500mg+ daily, but participants rarely report feeling different during the trial period. The metabolic benefits (improved insulin sensitivity, mitochondrial biogenesis, reduced oxidative stress) are measured via biomarkers, not symptoms. If you want confirmation, request whole blood NAD+ testing through a functional medicine provider. Several labs now offer this as a direct-to-consumer test, though it's not yet standard in conventional medicine.

What If I'm Taking 100mg Daily Because That's What the Bottle Recommends?

You're likely underdosing based on clinical trial standards. Most over-the-counter NAD+ supplements recommend 50–150mg daily because it lowers cost per bottle and avoids sticker shock, not because that dose is supported by human efficacy trials. Research published in Nature Communications found that 300mg NR produced inconsistent NAD+ elevation. Some participants showed a 15–20% increase, others showed none. The threshold for reliable, measurable NAD+ increase is 500mg daily for nicotinamide riboside and 250–500mg for nicotinamide mononucleotide. If cost is a constraint, consider switching to nicotinamide (niacinamide) at 250–500mg, which is significantly cheaper than NR or NMN and still raises NAD+ through the salvage pathway, though less efficiently.

What If I Have Insulin Resistance or Type 2 Diabetes — Does That Change the Dose?

Yes. Metabolic dysfunction increases the NAD+ precursor dose required to achieve therapeutic intracellular levels. Obesity and insulin resistance upregulate the NNMT enzyme, which methylates and degrades nicotinamide before it can be converted to NAD+. This creates a metabolic sink: more of the precursor is shunted to excretion rather than NAD+ synthesis. Our team has found that clients with fasting glucose above 100 mg/dL or HbA1c above 5.7% often require 750–1000mg NR daily to match the NAD+ elevation seen in metabolically healthy individuals at 500mg. If you're supplementing at standard doses without results, consider increasing to 750–1000mg and retest after eight weeks.

The Unfiltered Truth About NAD+ Dosing

Here's the honest answer: most NAD+ supplements on the market are dosed too low to produce the metabolic outcomes they imply on the label. Not slightly too low. Dramatically too low. A 100mg capsule of nicotinamide riboside taken once daily will not restore mitochondrial function, extend lifespan, or reverse cellular aging. It might raise NAD+ levels by 5–10% if you're lucky, but that's within the margin of daily physiological variation and unlikely to activate sirtuins, improve insulin sensitivity, or alter any measurable health marker.

The clinical evidence is clear: meaningful NAD+ elevation in humans begins at 500mg daily for NR and 250–500mg for NMN. Anything below that is supplementing at a dose that has not been validated in peer-reviewed trials. The supplement industry knows this. They dose low to keep cost per bottle competitive, not to match clinical efficacy. If a brand sells 60 capsules of 100mg NR for $30, you're paying $0.50 per dose but getting one-fifth of the clinically effective amount. A 500mg dose would cost $2.50 per day at that rate, which is why most brands avoid recommending it outright.

This doesn't mean NAD+ supplementation is a scam. It means the gap between marketing and evidence is enormous. If you're going to supplement NAD+, dose it at the level human trials actually used. If 500–1000mg daily is too expensive, don't reduce the dose to make it affordable. Switch to a cheaper precursor like nicotinamide or reconsider whether NAD+ supplementation is the right metabolic intervention for your current health priorities.

The right NAD+ dosage isn't what fits your budget or what the label suggests. It's what the clinical trials demonstrated works. 500mg nicotinamide riboside daily as a baseline, adjusted upward if you have insulin resistance, chronic inflammation, or elevated NNMT enzyme activity. Anything less is guesswork, and guesswork doesn't produce the mitochondrial support, metabolic resilience, or longevity outcomes NAD+ is capable of delivering when dosed correctly.

Start Your Treatment Now to work with prescribers who understand metabolic optimisation at the cellular level. Not just symptom management.